文献速递衰弱、肌少症与跌倒老年综合评估

衰老与肥胖背景下肌少症定义的探讨:UK Biobank初步结果

On the Definition of Sarcopenia in the Presence of Aging and Obesity-Initial Results from UK Biobank.
PubMed 文献 · J Gerontol A Biol Sci Med Sci · 2020-01-01

通过磁共振成像量化无脂肪组织肌肉体积(FFMV)和肌肉脂肪浸润(MFI),并采用性别与BMI匹配的虚拟对照组(VCG)提取FFMV/身高²的z评分(FFMVVCG),发现VCG调整可实现标准化并增强与住院/功能的关联,FFMVVCG与MFI联合可提供更完整的肌肉特异性描述以客观检测肌少症。

要点

  • 现行EWGSOP2阈值下肌少症患病率随BMI升高而降低,但低功能患病率随BMI升高而增加。
  • VCG调整的FFMV可实现跨BMI类别的标准化并增强与功能的关联。
  • FFMVVCG与MFI联合诊断低功能的性能最高。

核心结论

  • VCG调整的FFMV可实现跨BMI类别的适当肌少症评估并增强与功能的联系。
  • MFI与FFMV联合提供更完整、肌肉特异性且与功能相关的描述,有助于客观检测肌少症。

研究设计与样本

  • 通过磁共振成像量化FFMV和MFI,并使用性别与BMI匹配的虚拟对照组提取FFMVVCG。
  • 通过住院 nights、握力、爬楼梯、步行速度和跌倒探究FFMVVCG与MFI联合的价值。

主要发现

  • 现行阈值下肌少症患病率随BMI升高而降低:体重不足8.5%、正常体重4.3%、超重1.1%、肥胖0.1%。
  • 低功能患病率随BMI升高而增加。
  • 住院 nights、低握力、慢步行速度和无爬楼梯与MFI正相关(p < .05),与FFMVVCG负相关(p < .01)。
  • 仅MFI与跌倒相关(p < .01)。
  • FFMVVCG与MFI联合检测低功能的诊断性能最高。

关键数值与推荐

  • 现行肌少症阈值(EWGSOP2:DXA、握力)下肌少症患病率:体重不足8.5%、正常体重4.3%、超重1.1%、肥胖0.1%。
  • 住院 nights、低握力、慢步行速度和无爬楼梯与MFI正相关(p < .05),与FFMVVCG负相关(p < .01)。
  • 仅MFI与跌倒相关(p < .01)。

临床怎么用

  • 在肥胖老年人中,现行肌少症阈值可能低估肌少症风险,应关注低功能而非仅肌肉量。
  • 采用VCG调整的FFMV可跨BMI类别标准化肌肉量评估,增强与功能的关联。
  • 结合MFI与FFMVVCG可提高低功能检测的诊断性能,有助于客观识别肌少症。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Current consensus is to combine a functional measure with muscle quantity to assess/confirm sarcopenia. However, the proper body size adjustment for muscle quantity is debated and sarcopenia in obesity is not well described. Further, functional measures are not muscle-specific or sensitive to etiology, and can be confounded by, for example, fitness/pain. For effective detection/treatment/follow-up, muscle-specific biomarkers linked to function are needed. METHODS: Nine thousand six hundred and fifteen participants were included and current sarcopenia thresholds (EWGSOP2: DXA, hand grip strength) applied to investigate prevalence. Fat-tissue free muscle volume (FFMV) and muscle fat infiltration (MFI) were quantified through magnetic resonance imaging (MRI) and sex-and-body mass index (BMI)-matched virtual control groups (VCGs) were used to extract each participant's FFMV/height2 z-score (FFMVVCG). The value of combining FFMVVCG and MFI was investigated through hospital nights, hand grip strength, stair climbing, walking pace, and falls. RESULTS: Current thresholds showed decreased sarcopenia prevalence with increased BMI (underweight 8.5%/normal weight 4.3%/overweight 1.1%/obesity 0.1%). Contrary, the prevalence of low function increased with increasing BMI. Previously proposed body size adjustments (division by height2/weight/BMI) introduced body size correlations of larger/similar magnitude than before. VCG adjustment achieved normalization and strengthened associations with hospitalization/function. Hospital nights, low hand grip strength, slow walking pace, and no stair climbing were positively associated with MFI (p < .05) and negatively associated with FFMVVCG (p < .01). Only MFI was associated with falls (p < .01). FFMVVCG and MFI combined resulted in highest diagnostic performance detecting low function. CONCLUSIONS: VCG-adjusted FFMV enables proper sarcopenia assessment across BMI classes and strengthened the link to function. MFI and FFMV combined provides a more complete, muscle-specific description linked to function enabling objective sarcopenia detection.

来源:J Gerontol A Biol Sci Med Sci,查看原文。版权归原作者所有。

引用

  1. Linge J, Heymsfield SB, Dahlqvist Leinhard O, et al. On the Definition of Sarcopenia in the Presence of Aging and Obesity-Initial Results from UK Biobank. J Gerontol A Biol Sci Med Sci. 2020. PMID: 31642894. doi:10.1093/gerona/glz229

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。